← All trials
NCT05949593
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2023
- Primary completion
- Aug 31, 2027
- Completion date
- Nov 30, 2027
- First posted
- Jul 18, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 429
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Belite Bio, IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.